The present invention relates to a method for preventing and / or treating respiratory distress syndrome in a patient in need thereof, the method comprising the following steps:a) applying a nasal sustained airway pressure to the patient with a nasal device at a pressure of from 1 to 12 cm H 2 O；b) administering to the trachea of the patient a pulmonary surfactant suspended in a pharmaceutically acceptable medium by a tube having a diameter between 5 and 12 Fr, preferably by gastric intubation； Andc) removing said tube at termination of administration；Wherein the pulmonary surfactant suspension is added at a concentration of at least 40 mg / ml and has a viscosity lower than 20 mPas.Another aspect of the invention relates to the use of a pulmonary surfactant in the manufacture of a pharmaceutical composition for administration to a patient suffering from respiratory distress syndrome, the procedure of administration comprising the following steps:a) applying nasal persistent airways pressure (nCPAP) to the patient with a nasal device at a pressure of 1 to 12 cm H 2 O；b) administering to the trachea of the patient a pulmonary surfactant suspended in a pharmaceutically acceptable medium by a tube having a diameter between 5 and 12 Fr, preferably by gastric intubation； Andc) removing said tube at termination of administration；Wherein the pulmonary surfactant suspension is added at a concentration of at least 40 mg / ml and has a viscosity lower than 20 mPas.The invention further relates to a kit comprising:i) a pharmaceutical composition comprising pulmonary surfactant suspended in a pharmaceutically acceptable medium at a concentration of at least 40 mg / ml, said composition having a viscosity lower than 20 centipoise；Ii) a thin tube having a diameter comprising between 5 and 12 Fr；Iii) an apparatus for administering the surfactant at a controlled rate； AndIii) a receiving form for containing the dosage form, the thin tube and the device.Surfactant, respiratory distr
